vs

Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and WisdomTree, Inc. (WT). Click either name above to swap in a different company.

ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $147.4M, roughly 1.9× WisdomTree, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 27.1%, a 69.2% gap on every dollar of revenue. On growth, WisdomTree, Inc. posted the faster year-over-year revenue change (33.2% vs 9.4%). Over the past eight quarters, WisdomTree, Inc.'s revenue compounded faster (23.4% CAGR vs 17.5%).

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.

WisdomTree, Inc. is a global exchange-traded fund (ETF) and exchange-traded product (ETP) sponsor and asset manager with headquarters in New York. WisdomTree launched its first ETFs in June 2006, and became one of the major ETF providers in the United States. WisdomTree sponsors different ETFs that span asset classes and countries worldwide. Categories include: U.S. and International Equity, Currency, Fixed Income and Alternatives.

ACAD vs WT — Head-to-Head

Bigger by revenue
ACAD
ACAD
1.9× larger
ACAD
$284.0M
$147.4M
WT
Growing faster (revenue YoY)
WT
WT
+23.8% gap
WT
33.2%
9.4%
ACAD
Higher net margin
ACAD
ACAD
69.2% more per $
ACAD
96.3%
27.1%
WT
Faster 2-yr revenue CAGR
WT
WT
Annualised
WT
23.4%
17.5%
ACAD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACAD
ACAD
WT
WT
Revenue
$284.0M
$147.4M
Net Profit
$273.6M
$40.0M
Gross Margin
90.8%
Operating Margin
6.1%
40.5%
Net Margin
96.3%
27.1%
Revenue YoY
9.4%
33.2%
Net Profit YoY
90.3%
46.6%
EPS (diluted)
$1.61
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACAD
ACAD
WT
WT
Q4 25
$284.0M
$147.4M
Q3 25
$278.6M
$125.6M
Q2 25
$264.6M
$112.6M
Q1 25
$244.3M
$108.1M
Q4 24
$259.6M
$110.7M
Q3 24
$250.4M
$113.2M
Q2 24
$242.0M
$107.0M
Q1 24
$205.8M
$96.8M
Net Profit
ACAD
ACAD
WT
WT
Q4 25
$273.6M
$40.0M
Q3 25
$71.8M
$19.7M
Q2 25
$26.7M
$24.8M
Q1 25
$19.0M
$24.6M
Q4 24
$143.7M
$27.3M
Q3 24
$32.8M
$-4.5M
Q2 24
$33.4M
$21.8M
Q1 24
$16.6M
$22.1M
Gross Margin
ACAD
ACAD
WT
WT
Q4 25
90.8%
Q3 25
92.2%
Q2 25
92.2%
Q1 25
91.7%
Q4 24
91.6%
Q3 24
92.5%
Q2 24
92.5%
Q1 24
88.8%
Operating Margin
ACAD
ACAD
WT
WT
Q4 25
6.1%
40.5%
Q3 25
12.8%
36.3%
Q2 25
12.2%
30.8%
Q1 25
7.9%
31.6%
Q4 24
59.1%
31.7%
Q3 24
12.6%
36.0%
Q2 24
12.6%
31.3%
Q1 24
7.4%
28.9%
Net Margin
ACAD
ACAD
WT
WT
Q4 25
96.3%
27.1%
Q3 25
25.8%
15.7%
Q2 25
10.1%
22.0%
Q1 25
7.8%
22.8%
Q4 24
55.4%
24.7%
Q3 24
13.1%
-4.0%
Q2 24
13.8%
20.3%
Q1 24
8.0%
22.8%
EPS (diluted)
ACAD
ACAD
WT
WT
Q4 25
$1.61
$0.28
Q3 25
$0.42
$0.13
Q2 25
$0.16
$0.17
Q1 25
$0.11
$0.17
Q4 24
$0.86
$0.20
Q3 24
$0.20
$-0.13
Q2 24
$0.20
$0.13
Q1 24
$0.10
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACAD
ACAD
WT
WT
Cash + ST InvestmentsLiquidity on hand
$177.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
$413.7M
Total Assets
$1.6B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACAD
ACAD
WT
WT
Q4 25
$177.7M
Q3 25
$258.0M
Q2 25
$253.6M
Q1 25
$217.7M
Q4 24
$319.6M
Q3 24
$155.1M
Q2 24
$177.1M
$132.5M
Q1 24
$204.7M
$116.9M
Stockholders' Equity
ACAD
ACAD
WT
WT
Q4 25
$1.2B
$413.7M
Q3 25
$917.3M
$373.4M
Q2 25
$822.4M
$445.1M
Q1 25
$765.2M
$415.6M
Q4 24
$732.8M
$400.0M
Q3 24
$577.2M
$374.9M
Q2 24
$516.7M
$445.6M
Q1 24
$464.0M
$423.2M
Total Assets
ACAD
ACAD
WT
WT
Q4 25
$1.6B
$1.5B
Q3 25
$1.3B
$1.4B
Q2 25
$1.2B
$1.1B
Q1 25
$1.1B
$1.0B
Q4 24
$1.2B
$1.0B
Q3 24
$976.9M
$1.0B
Q2 24
$914.1M
$964.1M
Q1 24
$855.1M
$931.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACAD
ACAD
WT
WT
Operating Cash FlowLast quarter
$-48.7M
$147.9M
Free Cash FlowOCF − Capex
$147.7M
FCF MarginFCF / Revenue
100.2%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
-0.18×
3.70×
TTM Free Cash FlowTrailing 4 quarters
$240.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACAD
ACAD
WT
WT
Q4 25
$-48.7M
$147.9M
Q3 25
$74.3M
$48.1M
Q2 25
$64.0M
$38.8M
Q1 25
$20.3M
$6.4M
Q4 24
$40.4M
$113.5M
Q3 24
$63.2M
$47.7M
Q2 24
$25.0M
$32.2M
Q1 24
$29.1M
$-1.0M
Free Cash Flow
ACAD
ACAD
WT
WT
Q4 25
$147.7M
Q3 25
$73.9M
$48.0M
Q2 25
$38.7M
Q1 25
$6.3M
Q4 24
$113.3M
Q3 24
$63.2M
$47.7M
Q2 24
$32.2M
Q1 24
$-1.1M
FCF Margin
ACAD
ACAD
WT
WT
Q4 25
100.2%
Q3 25
26.5%
38.2%
Q2 25
34.4%
Q1 25
5.9%
Q4 24
102.4%
Q3 24
25.2%
42.1%
Q2 24
30.1%
Q1 24
-1.1%
Capex Intensity
ACAD
ACAD
WT
WT
Q4 25
0.1%
Q3 25
0.1%
0.0%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.1%
Q3 24
0.0%
0.0%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
ACAD
ACAD
WT
WT
Q4 25
-0.18×
3.70×
Q3 25
1.03×
2.44×
Q2 25
2.40×
1.57×
Q1 25
1.07×
0.26×
Q4 24
0.28×
4.15×
Q3 24
1.93×
Q2 24
0.75×
1.48×
Q1 24
1.76×
-0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACAD
ACAD

Nuplazid$174.4M61%
Daybue$109.6M39%

WT
WT

Investment Advisory Management And Administrative Service$122.7M83%
Other Services Income$12.7M9%
IE$11.5M8%

Related Comparisons